Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome. In this prospective, single arm, Phase 2 trial, 111 Dutch and Australian children aged 1-18 years with newly diagnosed, t(9;22)-negative ALL, were identified among 1041 consecutively enrolled patients as high risk (HR) based on clinical features or high MRD. The HR cohort received the AIEOP-BFM (Associazione Italiana di Ematologia ed Oncologia Pediatrica (Italy)-Berlin-Frankfurt-Mü nster ALL Study Group) 2000 ALL Protocol I, then three novel HR chemotherapy blocks, followed by allogeneic transplant or chemotherapy. Of the 111 HR patients, 91 began HR treatment blocks, while 79 completed the protocol. There were 3 remission failures, 12 relapses, 7 toxic deaths in remission and 10 patients who changed protocol due to toxicity or clinician/parent preference. For the 111 HR patients, 5-year event-free survival (EFS) was 66.8% ( ± 5.5) and overall survival (OS) was 75.6% ( ± 4.3). The 30 patients treated as HR solely on the basis of high MRD levels had a 5-year EFS of 63% (±9.4%). All patients experienced grade 3 or 4 toxicities during HR block therapy. Although cure rates were improved compared with previous studies, high treatment toxicity suggested that novel agents are needed to achieve further improvement.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy, with a cure rate 480%.
1,2 However, cure rates for the 10% of ALL patients identified as high risk (HR) using minimal residual disease (MRD) assays are only 20-50% and are equally poor after relapse. [3] [4] [5] [6] [7] [8] [9] Surrogate markers of in vivo treatment response during early treatment phases, such as MRD testing, are now the most powerful predictors of relapse. 6, 7, [10] [11] [12] In a study of the mechanism of relapse in ALL patients, we have previously shown that the relapsing clone is present at diagnosis as a minor population among most relapsing patients. 13 Moreover, an earlier Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG) trial, randomising ALL patients at 12 months from diagnosis to more intensive therapy, failed to reduce subsequent relapse risk. 4 These observations suggested that stratifying HR patients to different therapy early in first complete remission (CR1) may be a more effective strategy to prevent relapse. Strategies used to reduce relapse in HR patients have involved new agents, 14 intensification of existing chemotherapy and allogeneic stem cell transplantation (SCT) in CR1. [15] [16] [17] We developed a novel treatment regimen using existing cytotoxic agents to assess the effect of sequential courses of highly myelo-suppressive chemotherapy on clinical outcome and residual leukemic burden in patients with HR ALL, followed by SCT or further chemotherapy. Features identifying HR status were identical to those used in the recently published AIEOP-BFM (Associazione Italiana di Ematologia ed Oncologia Pediatrica (Italy)-BerlinFrankfurt-Mü nster ALL Study Group) ALL 2000 protocol. 6, 7 Each of our three HR treatment blocks was designed around chemotherapy regimens of proven value in relapsed or adult ALL: etoposide and cyclophosphamide; 18, 19 mitoxantrone and cytarabine; 20, 21 and, fludarabine, idarubicin and cytarabine. 22, 23 Oncology Group (DCOG) ALL10 protocol. They were treated at 14 child cancer centres in Australia, New Zealand and the Netherlands. A total of 111 (10.7%) patients (48 Australian and 63 Dutch patients) were eligible for enrolment. This analysis is based on a snapshot of the data taken on 31 December 2010. Ethics approval was obtained from institutional ethics committees and written informed consent was obtained from patients, parents or legal guardians. The study data were reviewed annually by a data safety monitoring committee.
PATIENTS AND METHODS Patients

HR features
Criteria for HR stratification were identical to those used in the AEIOP-BFM ALL 2000 study. 6, 7 Patients were identified as HR if the peripheral blood blast count response after day 8 of oral prednisone alone was 41.0 Â 10 9 /l (poor prednisone response (PPR)), the MRD level in the bone marrow aspirate at day 79 after initial diagnosis was 45 Â 10 À 4 , t(4;11) was present in the diagnosis marrow or there was an M3 marrow (425% blasts) at day 33.
Treatment
All patients received Pre-phase with prednisone alone plus one intrathecal dose of methotrexate, then Protocol IA and IB according to AEIOP-BFM ALL 2000. 6, 7 HR patients then received three novel 7-week blocks of intensive chemotherapy (Table 1) . Thereafter, HR patients with a suitable donor (n ¼ 57) were then eligible for an allogeneic SCT in CR1 if they had one of the following features: an MRD level 45 Â 10 À 4 in the bone marrow aspirate at day 79 after diagnosis, no CR at day 33, PPR and either M3 marrow at day 15 or T-cell phenotype or white blood cell count (WBC) 4100 Â 10 9 /l (high WBC (HWBC)). HR patients without these criteria or who were lacking a suitable donor (n ¼ 22) then repeated the three HR chemotherapy blocks, followed by AEIOP-BFM ALL 2000 Protocol II and oral maintenance chemotherapy with methotrexate (20 mg/m 2 ) and 6-mercaptopurine (50 mg/m 2 ) for a total treatment duration of 2 years from diagnosis. The HR protocol was amended in April 2004 because of excessive toxicity in patients not receiving SCT. Thereafter, the myelosuppressive chemotherapy doses for HR blocks 5 (mitoxantrone and cytarabine) and 6 (fludarabine and cytarabine) were reduced by 50%. Thus, patients (n ¼ 12) enrolled between October 2002 and April 2004 received twice the doses listed in Table 1 of mitoxantrone, cytarabine, fludarabine and cytarabine. Prophylactic cranial irradiation at a dose of 12 Gy was given to HR patients receiving chemotherapy alone during Protocol II but only if 43 years of age for Dutch patients. Those patients receiving SCT had cranial irradiation as a component of the total body irradiation (TBI) given during conditioning.
Supportive care
All patients received prophylactic oral co-trimoxazole and antifungal therapy during HR therapy. Dutch patients also received prophylactic ciprofloxacin. Granulocyte colony-stimulating factor was administered to all patients for 10-14 days from 24 h after the completion of each HR block. As a precaution, prophylactic peripheral blood stem cell collection and storage was recommended at the end of HR block 1.
Allogeneic stem cell transplant procedures
A total of 57 patients underwent SCT after three HR blocks. SCT procedures were not mandated as part of the protocol.
From the ANZCHOG cohort, 22 patients underwent SCT. Donor sources were: matched sibling (10), unrelated umbilical cord blood (9), matched unrelated adult (2), or a mismatched family donor (1) . All patients were conditioned with a regimen utilising TBI at a dose of 12 Gy in 6 fractions over 3 days. The most commonly used conditioning regimen was TBI, cyclophosphamide and thiotepa (13), followed by TBI, cyclophosphamide and fludarabine (5) . Both matched unrelated adult donor stem cell sources were CD-34 selected. Three of the SCTs were performed using allogeneic peripheral blood as the stem cell source.
Among the DCOG cohort, 35 of 45 patients who completed HR3 underwent SCT according to protocol DCOG ALL10. As stratification in ALL10 was based on the BFM-2000 study, the guidelines for SCT also follow the ALL SZT-BFM 2003 protocol. Dutch patients were conditioned with TBI, cyclophosphamide and etoposide. Donor sources were: matched sibling (16), matched unrelated donor (14) , mismatched unrelated donor (4), or a mismatched family donor (1) . Stem cell sources were: bone marrow (25), umbilical cord blood (6), or peripheral blood (4).
MRD assessments
MRD was measured in bone marrow samples by real-time quantitative PCR for immunoglobulin and T-cell receptor gene rearrangements, as previously described. [24] [25] [26] The data were interpreted using EuroMRD guidelines, 27 with quality control by the EuroMRD group. At least one MRD test with quantitative range of 5 Â 10 À 4 -5 Â 10 À 5 , and sensitivity of 1 Â 10 À 4 -1 Â 10 À 5 , was achieved for 90 of the 91 patients. We designed individual probes in four cases.
Statistical analysis
The primary aim of the study was to prospectively evaluate the clinical and molecular outcomes of HR ALL patients in first remission treated with HR block therapy and either SCT or chemotherapy. A secondary aim was to assess MRD levels following each HR block. The event-free survival (EFS) for N ¼ 111 eligible HR patients was defined as the time from diagnosis to first event (an event was defined as remission failure, relapse, withdrawal of consent, secondary malignancy or death from any cause) or to the date of b Triple intrathecal medication consisted of age-related doses of cytarabine, hydrocortisone and methotrexate.
Therapy for high-risk acute lymphoblastic leukemia GM Marshall et al last follow-up. The EFS for N ¼ 91 patients who received three HR blocks was defined as the time from diagnosis to first event or withdrawal from study or to date of last follow-up. Overall survival (OS) was defined as the time from diagnosis to the point of death from any cause. For EFS and OS, the primary analyses were Kaplan-Meier and log-rank tests. Multivariate Cox regression was used to assess the prognostic significance of HR features. Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE). 28 Safety was summarised for all the patients by the number of toxic effects during the trial scored at CTCAE grade 3 or higher and the proportion of patients having a serious adverse event. Each toxic effect was placed into one of the seven toxicity groups: haematological, infectious, gastro-intestinal, skin, renal, cardiac and neurological. Because a patient may have experienced both grade 3 and 4 effects from the same toxicity group during the same HR block, only the highest grade of toxicity was reported for each patient.
Some of the clinical trial costs were funded by grants from Cancer Council New South Wales and Cancer Institute New South Wales, while some of the MRD assay costs were funded by the Australian National Health and Medical Research Council (NHMRC). These funding bodies had no role in study design, data collection, data analysis, data interpretation or writing of this report. The authors had full access to the data and final responsibility for the decision to submit for publication. The study was registered with the NHMRC's Australian Clinical Trials Registry and had a reference number of ACTRN12607000302459.
RESULTS
HR patient characteristics
A total of 111 children with newly diagnosed t(9;22)-negative ALL, aged 1-18 years, were consecutively identified using clinical or MRD criteria as HR by the end of Protocol I and were eligible to receive the HR chemotherapy (Table 1 ). However, 20 eligible patients did not begin the HR chemotherapy, or were not assessable, due to: death in induction (1) failure to remit (3), treatment protocol changed due to toxicity (3) or clinician/ parent preference (5), and missing toxicity data (8) (Figure 1) . The remaining 91 patients commenced HR chemotherapy blocks. Clinical features that were more frequent among the HR cohort at diagnosis, compared with the entire ALL patient cohort, were male gender, age 410 years, T-cell and HWBC ( Table 2) . The majority of patients were stratified to HR therapy because of high MRD at day 79 (33%), PPR þ T-cell ( ± HWBC) (34%) or PPR alone (16%) ( Table 3 ). (Figure 1 ). After completing all three HR blocks, 8 patients changed protocol due to clinician/parent preference (2), severe respiratory syncytial virus infection during SCT conditioning (1), central nervous system relapse (1), anaphylaxis to PEGAsparaginase (1), intra-cerebral haemorrhage with thrombocytopenia (1), severe Escherichia coli sepsis (1) or prolonged myelosuppression and infection (1) .
Treatment
Of the 79 patients completing protocol therapy, 57 underwent SCT and 22 continued chemotherapy alone. Thirteen of the 22 patients who received chemotherapy alone, who had been assigned to receive a SCT, did not receive SCT due to the absence Therapy for high-risk acute lymphoblastic leukemia GM Marshall et al of a suitable donor or clinician/parent preference. Most of the 57 SCT patients had either high MRD (47%), or PPR þ T-cell þ HWBC (49%) as HR features, while chemotherapy alone patients had PPR alone (27%), PPR þ T-cell (45%), or t(4:11) (14%).
Toxicity
All 91 patients treated with HR blocks experienced at least one episode of grade 3 or 4 hematological toxicity requiring transfusions and hospitalisation for fever and neutropenia (Table 4) . Intensive care admission was required for one patient after HR1, three after HR2 and one after HR3. Most patients experienced a grade 3 or 4 gastrointestinal toxicity during HR1 (mucositis, vomiting or diarrhoea necessitating augmented nutrition). The intended duration of each HR block was 49 days. The median duration of HR1 was 48 days, compared with 49 days for HR2 and 54 days for HR3.
Clinical outcomes
The 5-year EFS for all 111 eligible HR patients was 66.8% ( ± 5.5) and OS 75.6% ( ± 4.3) (Figure 2a ) at 52 months (15-94) median follow-up. For the 91 patients who received three HR blocks, 5-year EFS was 76.5% (±4.6) and OS 79.6% (±4.5) (Figure 2b) . Among the 91 patients completing three HR blocks, there were 12 relapses (1 after three HR blocks but before SCT) and 7 deaths in remission.
HR patients with high MRD at day 79 alone (n ¼ 30) had a 5-year EFS of 63% ( ± 9.4) and OS of 69.8% ( ± 9.1), while those 15 patients with PPR alone had an EFS of 87.5% ( ± 11.7) and an OS of 100% (Table 2 ). Univariate analysis of HR features for OS demonstrated that patients with PPR alone had a significantly better outcome, compared with patients with either MRD alone (P ¼ 0.04) or no CR at day 33 (P ¼ 0.01). However, a comparison of EFS for patients with PPR alone to patients with either MRD alone (P ¼ 0.06) or no CR at day 33 (P ¼ 0.09) only approached statistical significance.
Nine of the 57 patients who underwent SCT after three HR blocks relapsed (8 bone marrow, 1 CNS). Only 3 of 9 relapsed patients are alive and free of disease, 7-36 months after relapse. Three patients who underwent SCT died from SCT-related complications. HR patients treated with SCT had a 5-year EFS of 73.3% ( ± 7.8) and OS of 82.7% ( ± 5.3). Among the 22 HR patients who received chemotherapy alone, there were 2 relapses and 4 late toxic deaths in remission, resulting in a 5-year EFS of 70.5% (±10.3) and an OS 76.4% (±9.3).
MRD responses and HR blocks
All 91 HR patients received HR blocks in the same order and so it is not possible to directly compare the anti-leukemic effect of individual HR treatment blocks. The most significant cytoreductive effect on MRD followed HR1 (Figure 3) . HR1 treatment caused an MRD reduction of 41 log in 45% of patients, compared with only 3% after HR2 and 11% after HR3. A small number of patients showed an increase in MRD following either HR2 (n ¼ 2) or HR3 (n ¼ 3). Among patients who received chemotherapy alone, HR4-6 blocks correlated with no significant changes in MRD levels, however, the patient numbers were too small to draw conclusions about the effectiveness of HR4-6. MRD was negative in 75% of all patients after three HR blocks (Figure 3) . Therapy for high-risk acute lymphoblastic leukemia GM Marshall et al
DISCUSSION
We report here a prospective, multicentre, single-arm, phase 2 trial for children with HR ALL in first remission treated in Australia, New Zealand and the Netherlands, showing an improved cure rate compared with other published series in similarly defined HR ALL patients but high treatment toxicity. 6, 7 The use of MRD measurements during each treatment component indicated that the highest level of cyto-reduction occurred after HR block 1. Our results compare favourably with most reports of HR ALL cohorts, but differences in the definition of HR status make direct comparisons difficult. [29] [30] [31] [32] Our criteria for HR treatment stratification were identical to those used for patients treated on the AIEOP-BFM ALL 2000 protocol. Two recent reports on the outcomes of ALL patients treated on the AIEOP-BFM ALL 2000 protocol demonstrated 7-year EFS of 46.6% for HR B-lineage ALL (n ¼ 189) and of 49.8% for T-lineage ALL (n ¼ 97), with median patient follow-ups of 4.0 and 5.6 years, respectively. 6, 7 Apart from an unexpectedly low EFS for HR patients on BFM 90 (31.9%), outcomes of HR patients in BFM 86, 95 and 2000 have been similar (45.3%-53.2%) despite changes in risk criteria and therapy. 5 Clinical outcomes for HR patients in our study were higher, with the 5-year EFS of 66.8% for all 111 eligible HR patients at a 4.4 year median follow-up.
The treatment of HR patients on our protocol and AIEOP-BFM ALL 2000 were designed to be very similar, apart from HR block therapy. The differences in HR therapy were: (i) dexamethasone in each HR block in the AIEOP-BFM protocol; (ii) the use of 2 g of cyclophosphamide in the AIEOP-BFM HR1, compared with 3.6 g in our HR1; (iii) the use of 4.0 g of cytarabine in the AIEOP-BFM HR1, compared with 1.05 g of etoposide in our HR1; (iv) the use of vindesine, daunorubicin and ifosfamide in the AIEOP-BFM HR2, compared with cytarabine 7.5 g and mitozantrone in our HR2; and (v) the use of 8.0 g cytarabine and 0.5 g of etoposide in the AIEOP-BFM HR3, compared with 7.5 g of cytarabine, 18 mg of idarubicin and 112.5 mg of fludarabine in our HR3. Although it is difficult to compare individual components of a multi-agent chemotherapy program without random patient assignment, it may be concluded that our HR blocks were effective in the absence of dexamethasone and that 3.6 g cyclophosphamide combined with etoposide in HR1 may be more effective than 2.0 g of cyclophosphamide and cytarabine. Our study also provided greater dose intensity compared with AIEOP-BFM ALL 2000, as our HR patients essentially received chemotherapy at 2 weekly intervals, compared with 3 weekly intervals for the AIEOP-BFM ALL 2000 HR protocol. Moreover, the 5-year EFS of 63% for HR patients with high MRD in our study is much higher than the 3-year relapse free survival of 25% seen in BFM 95 for patients defined by the same MRD criteria. HR block treatment led to considerable toxicity in all the patients, as exemplified by the high incidence of grade 4 toxicities, intensive care admission, prolonged hospitalisation and 6.3% incidence of death in remission. In addition, we believe the 9% (10/111) incidence of eligible patients declining to be treated on protocol therapy, or withdrawing after commencing HR block therapy, highlighted concerns of the parents and clinicians about treatment toxicity. Future HR protocols will seek to reduce the number and duration of HR blocks and improve infection prevention.
Our study was not designed to address the role of SCT in HR ALL. The use of SCT in HR ALL in first remission has correlated with reduced relapse in some studies but not others. 7, 15, 16, [33] [34] [35] The higher proportion of patients in our study receiving SCT (63%), compared with HR ALL patients treated on AIEOP-BFM ALL 2000 (57%), correlated with a better overall EFS. Patients in our study receiving SCT had a similar cure rate to those treated with chemotherapy alone; however, the latter group had a higher proportion with PPR or t(4:11) alone and no other HR features. Thus, we cannot conclude that SCT was a necessary factor in the high EFS achieved in our cohort.
The therapeutic strategy of using surrogate markers of in vivo treatment response during early treatment phases, before clinical relapse and consequently intensifying therapy is now possible with MRD measurement. The improved cure rate seen in our study demonstrated the utility of this approach and confirm the role of MRD as a powerful prognostic factor in ALL. [5] [6] [7] 14 
